Skip to content
Life Sciences Series B Founded 2009

Ethris

Developer of mRNA therapeutics for infectious diseases. It has two proprietary platforms for SNIM RNA technology (Stabilized Non-Immunogenic mRNA) for transcript therapy and SNIM RNA delivery system. The platforms enable the designing of mRNA for the protein of interest and chemical modification of the nucleotide backbone to bypass the innate immune response and targeted delivery. The pipeline includes therapeutics…

📍 Planegg, Germany · Pulmonology,

Funding snapshot

Last roundSeries B
Amount$11M
Date6 May 2025
Total raised$31M
Team size34

About

Developer of mRNA therapeutics for infectious diseases. It has two proprietary platforms for SNIM RNA technology (Stabilized Non-Immunogenic mRNA) for transcript therapy and SNIM RNA delivery system. The platforms enable the designing of mRNA for the protein of interest and chemical modification of the nucleotide backbone to bypass the innate immune response and targeted delivery. The pipeline includes therapeutics for COVID-19, respiratory diseases, and Primary ciliary dyskinesia (PCD). Ethris operates in the Pulmonology, Genomics, Gene Therapy sectors. The company focuses on Diversified, Therapeutics. The company has raised $31.3M in Series B funding. Notable investors include Europa, Laureus Capital, EU4health, Gates, Orbimed. Ethris was founded in 2009 and is headquartered in Planegg, Germany.

Business model

Pulmonology > Drugs > Diversified,

Genomics > Applied Genomics > Clinical Genomics > Therapeutics

Institutional investors

Europa Laureus Capital EU4health Gates Orbimed Walter Gusthav Bernd Gansbacher

Latest coverage

No articles yet.

Raising like Ethris?

Analyze your pitch deck before your next raise.

Analyze My Deck →